PCSK9 and Alzheimer disease: Nevertheless, this study strongly supports the idea that peripheral PCSK9 inhibition could be a novel and easily implementable tool to increase cerebral Aβ clearance, thus targeting Aβ brain accumulation in AD with already available FDA-approved PCSK9 inhibitors.